Abbott MediaRoom - Press Releases
Mother and son jogging Mother and son jogging Mother and son jogging Mother and son jogging
Abbott’s New Lab Automation System, GLP Systems Track, Receives FDA Approval, Providing Labs and Patients with Faster Results
  • First automation system in the U.S. for clinical labs featuring smart CAR technology, boosting lab performance and flexibility
  • Cutting-edge technology and scalable automation solution helps laboratories meet high-volume demand
  • Reduces turnaround time and removes at least 80% of manual steps, increasing reliability and minimizing errors to help provide patients quicker lab results

ABBOTT PARK, Ill., Dec. 14, 2023 – Abbott today announced its new, innovative automation solution, GLP systems Track™, has received approval by the U.S. Food and Drug Administration (FDA) and is now available in the U.S. GLP systems Track will offer laboratories cutting-edge features to support high-volume needs and maximize productivity.

GLP systems Track offers an array of new features for laboratories to optimize performance and safety, increase productivity and meet growing demand. The unique, fully customizable system provides flexibility for labs and enables staff to configure design to meet their specific needs.

“We know that our customers are seeking flexibility and scalability in their laboratory operations so they can meet ever-growing demand,” said Louis Morrone, executive vice president for Abbott’s core diagnostics business. “GLP systems Track addresses those needs, enabling labs to increase performance and improve the overall quality of their operations.”

GLP systems Track Features

GLP systems Track showcases the intelligent self-propelled single sample carrier – called CAR. Samples move independently, not attached to rigid, fixed mechanized track systems. This reduces mechanical failures that can stop the entire system, guaranteeing the continuity of the operation and the flexibility to change when the laboratory requires it.

The automation system is the first in the U.S. for clinical labs featuring this smart CAR technology, which allows samples in self-propelled cars to travel throughout the track without a belt. This increases flexibility for labs and helps boost performance. The smart CAR technology streamlines operations so labs can provide quick, accurate results and deliver the best care to patients and customers.

Up to 70% of medical decisions depend on lab test results. Abbott’s GLP systems Track can increase quality of care by automating lab operations while focusing on cost reduction in healthcare. The system’s unique technology makes work easier, faster and simpler. The laboratory automation solution takes the guesswork out of sample sorting and transportation.

The system offers several other advantages:

  • Allows samples to travel automatically throughout the system
  • Meets demand and maximizes output because it can be customized for each lab
  • Works in harmony with lab technicians and staff, making workflows more efficient
  • Helps ensure lab worker safety by minimizing contact with patients’ blood samples and preventing exposure to biomedical waste

Across different care settings, this automation system can handle a high number of test tubes each day, up to 25,000, improving turnaround time of test results for patients. It also can help reduce operational costs and eliminate manual errors.

GLP systems Track is not approved for use in U.S. blood donor and plasma testing laboratories.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at, on LinkedIn at, on Facebook at and on Twitter @AbbottNews.


For further information: Abbott Media: Patrick O’Connell, 847-282-2649; Abbott Financial: Ryan Aliff, 224-667-2299

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?


You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?